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VaccinationThe majority of multiple myeloma patients relapse with the current treatment strategies, raising the need for
alternative therapeutic approaches. Cellular immunotherapy is a rapidly evolving ﬁeld and currently being
translated into clinical trials with encouraging results in several cancer types, including multiple myeloma.
Murine multiple myeloma models are of critical importance for the development and reﬁnement of cellular
immunotherapy. In this review,we summarize the immune cell changes that occur inmultiplemyelomapatients
and we discuss the cell-based immunotherapies that have been tested in multiple myeloma, with a focus on
murine models.
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Multiple myeloma (MM) is a clonal B-cell malignancy characterized
by an accumulation of malignant plasma cells in the bone marrow, and
the presence of a monoclonal protein in the serum and/or urine, de-
creased normal immunoglobulin levels and lytic bone disease [1]. Stan-
dard treatment ofMM in patients up to the age of 65 years consists in an
initial induction based on the administration of immunomodulatory
agents (thalidomide or lenalidomide) or the proteasome inhibitor
bortezomib, combinedwith chemotherapy or dexamethasone, followed
by autologous stem cell transplantation (auto-SCT) and consolidation/
maintenance therapy. Elderly patients beneﬁt from combination thera-
py including novel agents, followed by prolonged maintenance therapy
until disease progression. However, despite improvement of results
with current drug therapies, the vast majority of patients relapse due
to the appearance or persistence of multidrug-resistant plasma cell
clones.
Immunotherapy is a promising ﬁeld in cancer research and includes
both non-cellular immunotherapy and cell-based immunotherapy.
Different forms of cellular immunotherapy with potent anti-myeloma
activity have been investigated and validated in pre-clinical in vitro
and in vivomodels. In fact, immunotherapy as a novel treatmentmodal-
ity might offer long-term disease control in MM patients. However,
numerous challenges have to be addressed before immunotherapy
can be broadly used to treat MM patients, such as the identiﬁcation of
an optimal target antigen for vaccination strategies, the occurrence of
myeloma resistance and the general immunosuppressive nature of
multiple myeloma which hampers immune cell-based treatment
approaches. Thus, addressing these challenges in murine models is of
great interest.
Several immunocompetent murine models of MM have been
established and have been of value for the preclinical investigation of
MM immunotherapy (Table 1). MOPC315 and similar cell lines (J558,
HOPC, …) are plasmacytoma-resembling transplantable myeloma
cells thatwere isolated fromgranulomas obtained after injectingminer-
al oil in the peritoneum of Balb/c mice [2]. The 5TMMmodel comprises
the transplantable 5T2MM and 5T33MM cell lines and the 5TGM1
subclone [3,4]. This model originates from aging C57BL/KaLwRij mice,
an inbred substrain of C57 black mice, in which a small proportion of
the animals spontaneously develop a myeloma-like disease with a pri-
mary localization of myeloma cells in the bone marrow, resulting in
anemia and bone lesions, closely resembling the human counterpart.
Conversely, immunodeﬁcient models have been developed to assess
the effectiveness of cellular immunotherapy in xenograft models of
human MM (Table 2). There is currently no ideal myeloma model that
accurately reﬂects all aspects of the disease and each model has its ad-
vantages and limitations. Therefore, it is important that investigators
chose adequate models for answering their questions.
In this review, we ﬁrst summarize the general immune alterations
observed inmultiplemyeloma.We provide an overview of the different
cellular immunotherapeutic strategies that have been tested in murine
MMmodels, i.e. transplantation-based and adoptive transfer-based im-
munotherapy and dendritic cell vaccination, and describe how immune
cells may be manipulated to overcome the MM-related immune sup-
pressive effects in order to eradicate themalignant clone. Relevant ﬁnd-
ings from in vitro studies as well as clinical studies are also discussed.
2. Immune cell alterations in multiple myeloma
Impairment of the immune system is a well-known phenomenon
associated with MM. It is involved in MM progression and responsible
for an increased risk of infections and secondarymalignancies inmyelo-
ma patients. On the one hand, this immune alteration is caused by the
suppression of normal hematopoiesis through replacement of the nor-
mal bone marrow by malignant plasma cells. However, suppression of
normal hematopoiesis can also occur at a relatively lowMM inﬁltrationrate due to MM-related microenvironmental changes that impair the
proliferation and function of the CD34+ hematopoietic stem and pro-
genitor cells [5].
Moreover, the immune system is actively suppressed by myeloma
cells and through their interactionwith themicroenvironment. This im-
mune suppression is related to several mechanisms including secretion
of immunosuppressive factors and recruitment of immune suppressive
cells byMM cells, deﬁcient antigen processing and presentation by host
antigen-presenting cells and inhibition of activated T cells via expres-
sion of co-inhibitory molecules by the malignant cells [6]. Both the
number and the activity of several immune effector cells (Fig. 1) are
affected by immune suppression in MM and this partially explains the
anti-neoplastic activity of non-cellular immunotherapies, such as im-
munomodulatory drugs, which are able to revert immune effectors to
their physiological functions [7–12].
2.1. T cells
T lymphocytes, i.e. CD4 helper T cells and CD8 cytotoxic T cells
(CTLs), play a crucial role in anti-tumor immunity. Inmyeloma patients,
several CD4 and CD8 T-cell abnormalities have been described, most
frequently a decrease of CD4 T cells [13–18]. Speciﬁcally, Schutt et al. re-
ported reduced levels of memory CD4 T cells (CD4+CD45RO+), as well
as activated CD3+HLA-DR+ T cells in the blood ofMMpatients [18]. The
decrease in total CD4 T cells was associated with a reduced survival, an
advanced disease stage and an increased relapse probability [15,16]. In
addition, viral antigen-speciﬁc CTL response is impaired inMMpatients,
which might partially explain the limited success of anti-myeloma im-
munizations [19].
Within the CD4 subset, different T helper (Th) subsets can be distin-
guished based on the secretion of distinct cytokine proﬁles. Th1 and Th2
cells cross-regulate each other's development, and the balance between
these cell types is important for an efﬁcient immune response. Th1 cells
produce interferon (IFN)-γ and interleukin (IL)-2 and play a role in cell-
mediated immunity, while Th2 cells promote humoral immunity and
produce IL-4, IL-5, IL-6, IL-10, IL-13 and IL-25 [20,21]. In myeloma pa-
tients, abnormal Th1/Th2 ratios have been reported [17,20,22]. Sharma
et al. describe a polarization towards Th2 cytokines alongwith Th1 sup-
pression [22] while others report a decrease of Th2 cells, leading to an
increased Th1/Th2 ratio [17]. The observations of Sharma et al. are sup-
ported byﬁndings in amurineMMmodel inwhich anti-myeloma activ-
ity of Th1 cells was reported [23], and by observations suggesting an
attenuation of Th1 responses induced byMM cells [24]. However, addi-
tional studies are needed to conﬁrm these ﬁndings.
Th17 cells, an IL-17 secreting subset of CD4 T cells, could also play an
important role inMM. TheMM-secreted cytokines transforming growth
factor (TGF)-β and IL-6 induce the differentiation of Th17. Subsequent-
ly, IL-17 promotesMM cell growth, resulting in a positive feedback loop
[25]. Indeed, increased proportions of Th17 cells have been observed in
blood and bone marrow from MM patients. This increase could also be
triggered by dendritic cells [26,27].
Several of these T-cell alterations might occur due to the excessive
production of TGF-β by MM cells, which suppresses T-cell responses
through the inhibition of the IL-2 autocrine pathway in these cells [8,
28]. In addition, Gorgun et al. demonstrated that MM cells induce the
expression of the suppressor of cytokine signaling (SOCS) 1 in CD4
and CD8 T cells, which is a negative regulator of IL-2, IFN-γ and IL-6 sig-
naling, thus attenuating Th1 and CTL responses [12,24].
Another T-cell suppressive mechanism involves the programmed
death 1 (PD-1) coinhibitory molecule, a transmembrane protein
expressed on activated T cells that is involved in T-cell homeostasis.
Binding of PD-1 to its ligand PD-L1 (B7-H1) generates an inhibitory sig-
nal, resulting in a reduction of T-cell proliferation and production of cy-
tokines, which counterbalances T-cell stimulatory signals [29]. In
contrast to normal plasmocytes, myeloma cells express PD-L1 [29–31]
and T cells from MM patients express increased levels of PD-1 [30].
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PD-L1 up-regulation on MM cells through IL-6 secretion. The presence
of PD-L1 on myeloma cells induces T-cell apoptosis and anergy of
tumor-speciﬁc CTLs in vitro, conﬁrming the importance of the PD-1/
PD-L1 axis in the impairment of anti-myeloma T-cell response. In addi-
tion, PD-L1 directly promotes myeloma progression, as PD-L1+ myelo-
ma cells display an increased proliferation rate and resistance to
chemotherapy compared to PD-L1− myeloma cells. In accordance
with these in vitro observations, high levels of PD-L1 on myeloma
cells in patients are associated with an increased myeloma inﬁltration
in their bone marrow and signs of clinical progression [32].
Regarding the repertoire of T-cell receptor (TCR) rearrangements in
MM patients, oligoclonal expansions within CD4 T cells and CTLs have
been described [33–35]. These expansions are likely generated through
a persistent stimulation by tumor-associated antigens, but their clinical
signiﬁcance is not yet clear. Further studies to elucidate the speciﬁcity
and responsiveness of these clones are of great interest for immuno-
therapy, for example idiotype (Id)-targeted vaccination. In fact, Id-
speciﬁc T cells are present in MM patients, but their role in anti-
myeloma immune response remains to be determined [36]. Interesting-
ly, a peripheral deletion of Id-speciﬁc CD4 T cells and functional T-cell
unresponsiveness were demonstrated in a murine plasmacytoma
model using TCR transgenic mice [37].
2.2. B cells and humoral immunity
A decrease in CD19+ B cells has also been reported in MM patients
[18,38,39] and B-cell levels were inversely correlated with disease
stage [39]. Indeed, humoral immune deﬁciency with reduced levels of
polyclonal immunoglobulins is awell-known phenomenon inmyeloma
[10,18] and is causedby both a decreased number of B cells, and by func-
tional defects in B cells in MM, such as a reduced ability to secrete im-
munoglobulins and to differentiate into antibody-secreting plasma
cells [38] and a reduced up-regulation of CD80 costimulatory receptor
expression in response to stimulation [40]. The production of TGF-β
by myeloma and stromal cells contributes to the inhibitory effects on
normal B-cell proliferation and antibody secretion [41].Fig. 1. Immune cell alterations in multiple myeloma. Multiple myeloma causes several immun
interactionwhile crossed bars indicate an inhibitory effect. (↑) increase, (↓) decrease, (Δ) chang
of their origin.2.3. NK and NKT cells
Natural killer (NK) cells mediate the lysis of cells that express
decreased major histocompatibility complex class I (MHC I) levels, like
virally infected or tumor cells. They express killing activating receptors,
such as natural cytotoxicity receptors (NCRs) andNKG2D, and killing in-
hibitory receptors (KIRs). The MHC I-like molecules MICA and MICB
(MHC I Chain-related protein A and B) are ligands for NKG2D activating
receptor. NK cell-mediated lysis is suppressed as long as inhibitory
signals are dominant through the binding of KIRs to their ligands on
target cells, such as MHC I. However, when MHC I is absent/down-
regulated, a strategy frequently used by tumor cells in order to evade
lysis by CTLs, activating signals on NK cells become dominant and target
cells are lysed [12,42].
Bone marrow-derived MM cells in early-stage disease are sensitive
to NK-cell lysis because of their lowMHC I and highMICA levels. In con-
trast, late-stageMM cells have a highMHC I and a lowMICA expression,
suggesting the emergence of NK-resistant subclones during disease pro-
gression [42]. These results are in accordancewith reports describing an
increase of NK-associated activationmarkers in early stageMM [43] and
reduced NK-cell levels in untreated MM [18].
Fauriat et al. described that NK cells fromMM patients express nor-
mal levels of NCRs andNKG2D. In contrast, the expression of 2B4/CD244
coreceptor and CD16 (Fc-receptor) is reduced. Since MM cells express
CD48, a ligand for 2B4/CD244, the down-regulation of 2B4/CD244 on
NK cells might be another immune escape mechanism of myeloma
cells. The decrease of CD16, an important mediator of the antibody-
dependent cell-mediated cytotoxicity (ADCC) function of NK cells,
could be due to continuous exposure to monoclonal immunoglobulins
in MM patients [44]. Moreover, NK cells from MM patients express
PD-1, whereas normal NK cells do not. Thus, expression of PD-L1 on
MM cells could decrease the NK-cell response against myeloma. This
was conﬁrmed by neutralization of the PD-1/PD-L1 axis with an anti-
PD-1 antibody, which resulted in enhanced anti-myeloma NK-cell func-
tion in vitro. Interestingly, lenalidomide down-regulates PD-L1 on MM
cells and could act synergistically with the anti-PD-1 antibody [31]. Al-
together, these ﬁndings underscore the interest of enhancing thee cell alterations, leading to a general immune paresis. Arrowheads indicate a stimulatory
e (sense not clear). The color of cytokines/receptors correspondswith the color of the cells
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duce myeloma cell lysis, and identify PD-1 as an interesting immuno-
therapeutic target on NK cells.
NKT cells are CD1d-restricted T cells which also display NK charac-
teristics. Different subtypes have been described: type I or invariant
NKT (Vα24+β11+) and type II NKT cells (Vα24−β11−). In patients
with progressive myeloma disease, type I NKT cells are functionally
defective due to a reduced ligand-dependent IFN-γ production [45]. In
addition, a distinct type II NKT population that binds to inﬂammation-
associated lysophospholipids present in the plasma of MM patients
has been identiﬁed [46].
2.4. Dendritic cells
Several reports describe numerical changes and diverse functional
defects of dendritic cells (DCs) in MM. Both myeloid and plasmacytoid
DCs and their precursors are decreased in MM patients [47–50]. In a
ﬁrst study, Brown et al. reported that tumor-derived TGF-β1 and IL-10
inhibit the up-regulation of CD80 and CD86 co-stimulatory molecules
on DCs fromMM patients [40]. Next, they conﬁrmed an impaired ability
to up-regulate CD80 inDCs fromstage I and IIImyelomapatients. Both IL-
12 and IFN-γ were able to neutralize this defect in CD80 up-regulation
[48]. Interestingly, the CD80/CD86-ligand CD28 is overexpressed on
MM cell surface during disease progression, and its engagement to
CD80/CD86 on stromal DCs directly transduces a pro-survival signal to
the myeloma cell, while simultaneously inducing the production of IL-6
and the immunosuppressive enzyme indoleamine 2,3-dioxygenase
(IDO) by DCs [51].
Other functional defects that were described in DCs from MM
patients include a reduced CD40 and CD80 expression, reduced MHC
expression levels, and a decreased capacity to stimulate allogeneic T-
cell proliferation and cytokine production by these cells [47,52]. These
functional defects are partially due to an IL-6-mediated inhibition of
DC development [47]. Moreover, loading of MM tumor antigens has
been shown to cause functional defects in DCs, which can be overcome
by vascular endothelial growth factor (VEGF) neutralization [53]. Simi-
lar observations were made in the murine 5TGM1 MMmodel in which
an inhibition of DC differentiation and function byMM cells via IL-6, IL-
10, and TGF-β and activation of p38 mitogen-activated protein kinase
(MAPK) signaling have been reported [54]. This inhibitory mechanism
was conﬁrmed in monocyte-derived DCs from myeloma patients and
p38 inhibition resulted in a restoration of DC function [55]. Restoring
or ensuring normal DC function might be of great interest for several
cellular immunotherapy approaches that depend on it.
2.5. Regulatory/suppressive cells
Regulatory T cells (Tregs) are characterized by a CD4+CD25+Foxp3+
phenotype and play an essential role in the prevention of autoimmunity
and the regulation of immune responses. They exert their suppressive
function through cell-to-cell contact or secretion of immunosuppressive
cytokines like TGF-β and IL-10 [56]. Initially, a decrease in Treg numbers
was reported in MM patients, along with a defect in their ability to sup-
press T-cell proliferation [57]. In contrast, several more recent studies
have concluded that the number of functionally intact Treg is increased
in MM patients [49,50,58–60]. These observations are in accordance
with observations made in several other malignancies [56], and suggest
that MM cells evade immune surveillance partially through the increase
of suppressive Tregs [60]. The myeloma-promoting role of Tregs is re-
inforced by observations in MM patients showing a shorter survival for
patients with high Treg percentages [50] and indicating that the number
of Tregs is a predictivemarker for the risk of disease progression [60]. The
ﬁnding that MM cells are able to induce the generation of Tregs in vitro
further corroborates these results [61]. Furthermore, Tregs have been
shown to expand and accumulate in the bone marrow of MM patients
after allogeneic stem cell transplantation, and Tregs found in thesepatients are endowed with a strong inhibitory function, potentially
inhibiting anti-myeloma immune control after transplantation [62].
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous
population of immature myeloid cells with immune suppressive prop-
erties. MDSCs have been shown to accumulate in cancer patients,
through tumor- and stromal-secreted pro-inﬂammatory mediators,
and are able to facilitate tumor growth by hampering anti-tumor immu-
nity. Although their phenotype in humans is not yet well-deﬁned, they
are generally delineated as CD11b+CD33+HLA-DR− and comprise
monocytic and granulocytic/neutrophil-like subpopulations [63]. An in-
crease of MDSCs in peripheral blood and bone marrow of MM patients
has been observed [49,64,65]. Moreover, MDSCs induce MM growth
and suppress T-cell mediated immune responses, whileMM cells induce
MDSC development, resulting in a bidirectional interaction [64]. In mu-
rine models, myeloma disease enhances the immunosuppressive capac-
ity of MDSC in the bone marrow [66], and MDSCs play a critical role in
MM progression at early stages of disease [65]. Interestingly, it has
been shown that MDSCs are able to induce Treg differentiation in vitro,
although it is not clear at this point whether this occurs in MM [67]. Fur-
thermore, the speciﬁc contribution of MDSC subsets to MM progression
is notwell understood. Thus, overcoming or circumventing the immuno-
suppressive environment mediated by Tregs and MDSCs is an important
challenge for cell-based immunotherapy.3. Transplantation-based immunotherapy in multiple myeloma
3.1. Allogeneic transplantation in MM patients
Allogeneic stem cell transplantation (allo-SCT) is an active form of
immunotherapy used in numerous hematological malignancies. This
strategy presents amultifold interest. First, malignant cells are eradicat-
ed through a myeloablative conditioning treatment using high-dose ir-
radiation and/or chemotherapeutic drugs. Next, patients receive an allo-
SCT to rescue the patient aftermyeloablative conditioning. Moreover, as
an advantage compared to auto-SCT, donor immune cells in allo-SCT are
able to recognize and eradicate the potential residual malignant cells
after transplantation, a characteristic known as graft-versus-tumor ef-
fect. Of note, reduced-intensity conditioning regimens (RIC) have re-
cently been introduced, which allow transplantation in patients that
are considered too high risk for myeloablative conditioning.
In MM patients there is evidence of a graft-versus-myeloma (GvM)
effect. Donor lymphocyte infusions (DLIs) are capable of inducing a
complete response in relapsed patients [68] and the association of
chronic graft-versus-host disease (GvHD) with a reduced relapse rate
after transplantation further supports the existence of a GvM effect
[69,70]. In addition, it has been shown that long-term disease control
can be achieved in a subset ofMMpatients after allo-SCT [71]. However,
important challenges remain, as allo-SCT inMM is still associatedwith a
relatively high relapse rate that could be explained by the immune
suppressive phenotype of residual MM cells [8]. Moreover, the use of
allo-SCT in MM also represents a certain risk of GvHD and transplant-
related mortality, despite the use of RIC regimens. Several studies,
including phase III multicenter studies, compared auto-SCT followed
by RIC allo-SCT (auto-allo-SCT) to a tandem auto-SCT approach [70,
72–78]. Auto-allo-SCT was not superior to tandem auto-SCT in patients
with high-risk de novo MM [72] or in patients with standard-risk dis-
ease [70]. In newly diagnosed MM, despite encouraging progression-
free survival in auto-allo-SCT arm, this regimen was associated with
high morbidity and mortality and thus not beneﬁcial compared to tan-
dem auto-SCT [74]. Another study showed, in contrast, an overall bene-
ﬁt for auto-allo-SCT arm in newly diagnosedMMwith superior survival
[73]. Moreover, long-term outcome was better in patients that received
auto-allo-SCT rather than tandem auto-SCT [75,77]. Finally, in patients
that relapsed after the ﬁrst auto-SCT, controversial results have been
shown regarding the feasibility of allo-SCT as salvage therapy compared
Table 1
Cellular immunotherapy in immunocompetent murine myeloma models.
MM model Cellular immunotherapy
Murine cell
line
Origin In vivo growth Type Anti-myeloma effect? Ref
5TMM in C57Bl/KalwRij mice
5T2MM Spontaneous MM BM tropism Adoptive transfer (Tregs) No (increased MM progression) [87]
5T33MM Spontaneous MM BM tropism AlloSCT/DLI (C3.SW-H2b/Snj donor) Yes (extended with DC-vaccinated donor) [82]
Adoptive transfer (chNKG2D-expressing
T cells)
Yes + protective immune response [88]
Adoptive transfer (NK cells) + systemic
IL-2 treatment
Yes [96]
5TGM1 m BM tropism Adoptive transfer (Id-speciﬁc CTL or Th1) Yes [23]
DC vaccination (Id-KLH-pulsed or
tumor-lysate-pulsed)
Yes + protective immune response [138,141]
Mineral oil-induced plasmacytoma in Balb/c mice
HOPC-1F Induced plasmacytoma Extramedullar
plasmacytoma
Allo-SCT (DBA/2 donor) Yes (only with Id-vaccinated donor) [81]
Auto-SCT + Id-pulsed DC vaccination Yes [129]




Yes + protective immune response [140]
J558L J558 without H-chain Extramedullar
plasmacytoma
DC vaccination (Id-KLH-loaded) No [137]
DC vaccination (myeloma cell-loaded) Yes [137]









Yes + protective immune response [94]
VKCK SP2/0Ag14 cells expressing chimeric
light chain of ccM4 antibody
Extramedullar
plasmacytoma
Adoptive transfer (T cells or CTL) Yes [92]
Adoptive transfer (CD4 T cells from
VKCK-γ I/II-vaccinated mice)
Yes + protective immune response from
VKCK-γ (I/II) vaccination
[93]
MOPC315.4 Induced plasmacytoma Extramedullar
plasmacytoma
Adoptive transfer (Id-speciﬁc T cells from
TCR-transgenic donors)
Yes (dependent on CD4 T cells) [89]
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remains a controversial therapy for MM.
In order to improve the results of allo-SCT in MM, the use of immu-
nomodulatory agents after transplantation could be of interest in order
to increase the GvM effect and/or to decrease the severity of GvHD.
However, caution is warranted, as the use of lenalidomide as mainte-
nance therapy after allo-SCT might be associated with an unacceptable
risk of GvHD [79]. In contrast, the use of bortezomib after RIC allo-SCT
in combination with DLI seems to be feasible [80]. Thus, given the con-
troversial status of allo-SCT inMMand the potential risk associatedwith
the use of immunomodulatory agents in an attempt to modulate the
balance between GvM and GvHD, further studies are required. Murine
models are of great interest for this because they permit speciﬁc study
of the GvM versus GvHD reactivity and allow for testing new therapeu-
tic strategies prior to human trials.3.2. Allogeneic transplantation in immunocompetent murine MMmodels
The ﬁrst murine MMmodel in which allo-SCT-based immunothera-
py was tested consisted in Balb/c mice (H-2d) injected intraperitoneally
with HOPC-1F MM cells. Two days later, these mice were lethally irra-
diated and transplanted with cells from MHC-matched (H-2d) DBA/2
donors [81]. In this model, mice transplanted with unmanipulated
bone marrow cells could not achieve long-term disease-free survival
(N180 days). Only a moderate GvM effect was observed after co-
administration of splenocytes, with 8% ofmice achieving long-term sur-
vival. In contrast, bonemarrow grafts derived from Id-protein vaccinat-
ed donor mice resulted in a signiﬁcant GvM response, with 63% of mice
achieving long-term disease-free survival, which was further increased
when splenocytes from the same donor were co-administrated. Inter-
estingly, donor Id-vaccination did not increase the incidence of severe
acute GvHD in recipient mice. Finally, in vitro data suggested that allo-
geneic Id-speciﬁc CD8 T cells were implicated in the GvM response, as
these cells mediated speciﬁc lysis of HOPC-1F cells. Thus, donor immu-
nization can induce strong GvM effects after allo-SCT in the Balb/c
HOPC-1F model. However, this model poorly resembles human MMdisease, as myeloma cells are injected intraperitoneally and give rise
to abdominal tumors.
Next, a murineMM allo-SCTmodel was established in which C57Bl/
KaLwRij.Hsd (H-2b) recipient mice received irradiation followed by
allo-SCT from MHC-matched C3.SW-H2b/SnJ donors. After an immune
reconstitution period of two months, recipients were inoculated with
the 5T33MM murine cell line and developed myeloma disease. Post-
transplantation immunotherapy using DLI prolonged the median sur-
vival of diseased mice. Additional DC vaccination of the DLI-recipient
mice, using DC loaded with the H7 minor histocompatibility antigen
that differs between donor and recipient strains, further extended sur-
vival without inducing GvHD by targeting the H7-presenting MM
cells. Percentages of effector memory CD8 T cells were increased in
the bone marrow of transplanted MM mice, irrespective of post-
transplantation treatment. Furthermore, both MM growth and post-
transplantation immunotherapy (DLI plus DC vaccination) caused a de-
crease of the homeostatic bone marrow-homing chemokine stromal
cell-derived factor 1 (SDF1/CXCL12) levels and a strong induction of in-
ﬂammatory chemokine expression in the bone marrow of recipient
mice along with an increased expression of inﬂammatory homing re-
ceptors on donor T cells. This promoted an inﬂammation-driven migra-
tion of T cells towards the bonemarrow, possibly contributing to amore
effective GvM response [82].
So far, no studies have been reported in which allo-SCT was used
after the establishment of MM in immunocompetent murine models
that resemble human diseasemore closely, i.e. displaying bonemarrow
tropism.3.3. Xenogeneic transplantation in immunodeﬁcient murine MMmodels
A xenograft model was developed by Rozemuller et al. by engrafting
GFP/luciferase-transfected human MM cell lines into immunodeﬁcient
RAG2−/−γc−/− mice. This model allows bioluminescence imaging of
MM development, and myeloma cells preferentially inﬁltrate the bone
marrow as in human disease. After infusion of myeloma-bearing mice
with high doses of allogeneic human peripheral blood mononuclear
Table 2
Cellular immunotherapy in immunodeﬁcient murine xenograft models with human myeloma cells.
MM model Cellular immunotherapy
Human myeloma cells Immunodeﬁcient
recipient mice
In vivo growth Type Anti-myeloma effect? Ref
U266 RAG2−/−γc−/− BM tropism Allo-transplantation
(human PBMC)
Yes [83]
RPMI-8226/S RAG2−/−γc−/− BM tropism Allo-transplantation
(human PBMC)
Poor GvM response [83]
RPMI-8226 CD122-depleted NOD/SCID BM tropism Human naive T-cell transfer Yes [84]
NSG SC plasmacytoma Adoptive transfer
(anti-BCMA CAR T cells)
Yes [115]
NOD/SCID SC plasmacytoma Adoptive transfer
(anti-Lewis CAR T cells)
Yes [116]
U266 or RPMI-8226 or LME-1 RAG2−/−γc−/− Diverse Allo-transplantation
(human PBMC)





Impairment of GvM response
for extramedullar myeloma,
but not for BM-residing myeloma
[85]
OPM2 or primary MM Human fetal bone
xenograft in NOD/SCID/IL2Rγnull
BM tropism Adoptive transfer
(expanded human NK cells)
Yes [98]
ARP-1 NOD/SCID/IL2Rγnull BM tropism Adoptive transfer
(umbilical cord blood-derived
expanded human NK cells)
Yes [100]
RPMI-8226 or ARH-77 NOD/SCID SC plasmacytoma Adoptive transfer
(anti-CD138 CAR NK cells)
Yes [110]
IM9 NSG BM tropism Adoptive transfer
(anti-CS1-CAR NK cells)
Yes [107]
IM9 or MM1.S NSG BM tropism Adoptive transfer
(anti-CS1-CAR T cells)
Yes [111]
OPM2 NOD/SCID/IL2Rαnull BM tropism Adoptive transfer
(anti-CD56 CAR T cells)
Yes [113]
MM1.S NSG BM tropism Adoptive transfer
(anti-CD44v6 CAR T cells)
Yes [117]
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was observed in the U266MMmodel following the development of xe-
nogeneic GvHD. Lower doses of PBMCs did not lead to tumor clearance,
and almost all thesemicewere free fromGvHD, underlining the link be-
tween GvM and GvHD in this model. When inoculating the less immu-
nogenic MM cell line RPMI-8226/S, the GvM response was poor.
Nevertheless, these mice developed GvHD, underlining that less immu-
nogenic tumors can evade the GvM response despite the occurrence of
GvHD [83].
Another xenogeneic GvM model has been described by Freeman
et al. After injection of GFP/luciferase-transfected human RPMI8226
human MM cells into CD122-depleted NOD-SCID mice, they obtained
a MMmodel with bone marrow inﬁltration and bone lesions. Adoptive
transfer of human naive T cells into myeloma-bearing mice transiently
suppressed myeloma growth and signiﬁcantly prolonged survival. In
this model, myeloma cells induced the generation of allo-reactive T
cells in the inﬁltrated bones that exerted cytotoxic activity against resi-
dent myeloma cells. Further analysis of allo-reactive T cells revealed a
pronounced in vivo proliferation of CD8 T cells that became the domi-
nant T-cell type. Surprisingly, non-conventional, double-positive
CD8+CD4+ cell levels also increased in myeloma-inﬁltrated bones.
Both CD8 and double-positive T-cell subsets had an effector memory
phenotype, and MHC I expression on myeloma cells and cell contact
with T cellswas required for CD8 T-cell proliferation anddouble positive
T-cell development. Although the function of double positive T cells is
not completely understood, a higher proportion of these cells express
cytotoxic mediators such as IFN-γ and perforin compared to CD8 T
cells, suggesting that they could be involved in the GvM effect as well
[84].
In order to study the effect of Treg infusions on the GvM and GvHD
effect, RAG2−/−γc−/− immunodeﬁcient mice bearing various human
MM tumors were infused with human PBMCs alone or together with
cultured autologous Tregs [85]. Human PBMC infusions alone induced
variable GvM responses, depending on the degree of immunogenicityand growth rate of the myeloma cells. In addition, lethal xenogeneic
GvHD was observed. Co-infusion of Tregs inhibited lethal xenogeneic
GvHD, as observed by other groups of investigators [86], and did not im-
pair the GvM response against myeloma residing in the bone marrow.
However, it did impair anti-tumor responses against myeloma growing
outside of the bone marrow. In view of these results, the authors
showed that the bone marrow stroma is able to neutralize the sup-
pressive activity of Tregs through the production of IL-1β and IL-6. In
addition, Tregs could convert into Th17 cells in the bonemarrowmicro-
environment of the recipient mice [85].
4. Adoptive cell transfer in multiple myeloma
Because the modalities of transplantation and adoptive transfer-
based therapies sometimes overlap, we chose to categorize therapies
in which transplanted cells can give rise to immune reconstitution in
the recipients, i.e. mice that are immunodeﬁcient and/or underwent a
conditioning treatment, as a transplantation-based immunotherapy. In
contrast, adoptive cell transfer mainly aims at transmitting speciﬁc im-
munological and functional characteristics of the transferred cells into
recipients, which might remain completely immunocompetent, in
order to enhance the anti-tumor immune response.
4.1. Adoptive T-cell transfer
Adoptive transfer of Tregs from 5T2MM-bearing immunocompetent
C57/KalwRij mice into syngeneic mice led, in contrast to Treg infusions
in the previously described xenogeneic transplantation model [85], to
increased progression of MM disease in recipient mice [87]. These re-
sults suggest that cultured Tregs in xenogeneic murine transplantation
models are susceptible to bone marrow stroma-mediated neutraliza-
tion of their suppressive activity, while Tregs isolated from myeloma-
bearing syngeneic mice may be less susceptible to this neutralization
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needed to elucidate these ﬁndings.
Several other adoptive T-cell transfer strategies have been explored
inmurinemodels and some of these strategies are now being translated
to the clinic. 5T33MM myeloma cells express NKG2D ligands and the
adoptive transfer of T cells expressing a chimeric NKG2D receptor
(chNKG2D) fused to the CD3ζ cytoplasmic domain was tested in
5T33MM-bearing mice. Two infusions of chNKG2D T cells led to
tumor eradication in all animals, both through a direct anti-tumor effect
and by enhancing host T- and NK-cell immune responses. Moreover,
surviving mice developed a protective and speciﬁc immune response
against myeloma re-challenge, suggesting that chNKG2D T-cell adop-
tive therapy may be an effective form of immunotherapy in MM [88].
Anti-tumor effects of adoptively transferred Id-speciﬁc T cells have
also been demonstrated. Hong et al. generated CD8 CTL, CD4 Th1 and
Th2 Id-speciﬁc T-cell clones fromC57/KalwRijmice previously vaccinat-
ed with Id-pulsed DC. Adoptive transfer of Id-speciﬁc CD8 CTL and Th1
clones into 5TGM1-myeloma bearing mice resulted in myeloma eradi-
cation. In contrast, administration of Th2 cells had no effect, suggesting
that CTL and Th1 cells are tumoricidal [23]. Bogen et al. demonstrated
that adoptive T-cell transfer from TCR-transgenic mice, whose T cells
recognize an Id-peptide derived from the murine MOPC315 myeloma
protein, conferred anti-myeloma immunity to SCID mice challenged
with MOPC315.4 tumors. CD4 T cells are essential for this protection
as CD4 depletion led to tumor development in all the challenged mice,
whereas the role of CD8 T cells is less clear, as some but not all of the
mice developed tumors following CD8 depletion [89].
A synergistic effect between adoptive T-cell therapy and intra-
tumoral gene transfer of lymphotactin or IFN-γ-inducible protein-10
(IP-10), which are chemoattractants for T cells, has been shown in
Balb/cmice challengedwith SP2/0myeloma tumors [90,91]. In addition,
inoculation of modiﬁed VKCKmouse myeloma cells that secrete the fu-
sion protein RM4/IFN-tau in syngeneic Balb/c mice yielded an immune
response that involved CD8 CTLs. In fact, adoptive transfer of T-cell
enriched spleen cells or CTLs conferred protection against more aggres-
sive parental VKCK cells in this model [92]. Vaccination of syngeneic
mice with IFN-γ-secreting VKCK cells that express increased levels of
MHC I and MHC II resulted in a protective immune response against
the parental VKCK myeloma challenge. This protection was mediated
by both cytolytic CD4 and CD8 T cells. In addition, these tumor-
speciﬁc CD4 T cells are tumoricidal in adoptive transfer experiments
[93]. Vaccination against SP2/0 myeloma by transfer of tumor antigen-
speciﬁc lymphocytes into lymphopenic Balb/c mice, immunized with
IL-21-secreting SP2/0 myeloma cells, was successful [94]. Whether
gene therapy of MM cells or the described vaccination approaches can
be translated to the clinic remains to be determined.
4.2. Adoptive NK-cell transfer
In contrast to T cells, NK cells do not require pre-activation or immu-
nization in order to recognize and kill target tumor cells [95]. The ther-
apeutic potential of NK-cell adoptive transfer was demonstrated in the
5TMM myeloma model. In this model, IL-2 administration to MM-
bearing mice signiﬁcantly prolonged survival. This effect was abolished
by in vivo depletion of NK cells but not CD8 T cells. Moreover, activated
NK cells had the capacity to kill 5TMM cells in vitro. Finally, a combina-
tion of activated NK-cell adoptive transfer with systemic IL-2 treatment
resulted in an in vivo anti-MM effect that was dose-dependent on the
number of transferred NK cells [96]. Of note, a similar approachwas un-
dertaken in MM patients that were infused with IL2-stimulated KIR-L-
mismatched haplo-identical NK cells. Although this approach appeared
safe and feasible, several limitations became apparent, such as the difﬁ-
culty to collect a sufﬁciently high dose of allo-reactive NK cells by
leukapheresis, resulting in a limited eradication ofMM cells, and the ab-
sence of appropriately KIR-L mismatched donors for one third of other-
wise eligible patients [97]. These limitations led researchers to evaluatethe applicability of in vitro expansion of reactive NK cells. Garg et al. re-
cently described the expansion of NK cells from both MM patients and
healthy donors by co-culturing PBMCs with modiﬁed K562 cells, a
human leukemia cell line, and conﬁrmed the in vitro cytolytic activity
of these expanded NK cells against MM cell lines and primary MM
cells [98]. Blocking studies identiﬁed that multiple NK-cell receptors
work in a concerted manner to achieve perforin-dependent cytolysis.
Furthermore, adoptive transfer of these expanded NK cells inhibited
tumor development in a NK-cell dose-dependent manner in a human-
ized xenograft MMmodel, in which fetal human bones were implanted
into immunodeﬁcient NOD/scid/IL2Rγnull mice, followed by inoculation
with primary MM cells or the human myeloma cell line OPM2 [98]. A
phase II clinical trial examining the therapeutic effect of expanded
NK cells in relapsing high-risk MM patients is currently ongoing
(ClinicalTrial.gov #NCT01313897). In this study, NK cellswill be admin-
istrated after lymphocyte depletion to facilitate further expansion by
Treg-depletion and increased availability of homeostatic cytokines. In
addition, patients will be treated with bortezomib, which is known
to downregulate MHC I, increase TRAIL-mediated apoptosis and up-
regulate DNAM-1 and NKG2D NK-cell ligands to further sensitize MM
cells to NK cell-mediated lysis [98].
As an alternative, the use of human umbilical cord blood instead of
allogeneic PBMCs as anNK-cell sourcewas investigated [99]. Functional
NK cells could be obtained after in vitro expansion with IL-2. Moreover,
NK-cell expansion from cryopreserved cord blood units using artiﬁcial
antigen-presenting feeder cells was recently reported. The expanded
NK cells displayed in vitro cytotoxicity against several humanmyeloma
cell lines, and administration of these cells delayed tumor formation and
prolonged survival of MM-bearing mice in a xenogeneic mouse model
in which ARP-1 human myeloma cells were grafted in NOD/scid/
IL2Rαnullmice [100]. In addition, approaches to enhanceNK-cell activity
are also explored. For example, IPH2101, a monoclonal antibody that
blocks KIR-ligand interaction, in combination with lenalidomide aug-
ments the killing of autologousMM cells by NK cells [101]. In fact, treat-
ment of mice bearing the lenalidomide-resistant RMA T-cell lymphoma
with this combination led to in vivo tumor elimination [102]. Recently,
the results of a phase I and a phase II clinical trial with IPH2101 have
been reported in patients with relapsed/refractory or smoldering MM,
respectively [103,104]. Although deemed safe, the phase II clinical trial
showed no clinical response to IPH2101 alone. Altogether, these studies
suggest that increasing NK-cell sensitivity or activity in MM patients
prior to adoptive NK-cell transfer might be useful.
4.3. Adoptive chimeric antigen receptor T & NK-cell transfer
The anti-myeloma effects of both T and NK cells can be further in-
creased by transfecting these cells with chimeric receptors speciﬁc for
cell-surface molecules expressed on MM cells. These antigens include
the common plasma cell markers CD38 and CD138, but also less charac-
teristic targets (Table 3). The extracellular domain of a chimeric antigen
receptor (CAR) consists of the Fab region of an antibody, typically
engineered into a single-chain variable fragment and yielding speciﬁcity
to the CAR,whereas the intracellular domain is derived from the human
TCR signaling domain (CD3ζ), which may be fused to additional co-
stimulatory proteins that promote T-cell proliferation, cytokine release
and resistance to apoptosis [105,106]. CARs were initially transfected
into T cells and more recently this approach was also tested in NK cells.
Chu et al. engineered humanNK cells to express a CAR that is speciﬁc
to CS1 [107]. CS1 is a cell surface glycoprotein that is highly expressed
on MM cells, while expression is low on NK cells, some T-cell subsets,
normal plasma cells, and negligible on myeloid cells, hematopoietic
stem cells and the majority of healthy tissues [108]. Although the
exact role of CS1 in normal plasma cells is unknown, CS1 co-localizes
with CD138 on the surface of MM cells and promotesMM-cell adhesion
and clonogenic growth [109]. The intracellular part of anti-CS1 CAR
(CS1 CAR) contains a CD28–CD3ζ co-stimulatory signaling domain
Table 3
Molecular targets used for chimeric antigen receptor-based immunotherapy in murine multiple myeloma models.
Antigen Function Expression Ref
Normal cells Myeloma cells
CD38 Cell surface glycoprotein, ectoenzyme that
synthesizes cyclic ADP-ribose
—Mature B and T cells (low levels)
— NK cells
— Common myeloid progenitors
Surface expression at variable
levels in the majority of patients
[112]
CD138 Membrane heparan sulfate-containing
proteoglycan, participates in
cell–matrix interactions
— Pre-B cells and plasma cells
(lost on circulating/mature cells)
— Squamous epithelial cells
(strong membranous/some
cytoplasmic expression)
Expression at variable levels
by most myeloma cells
[110]
CD56 Cell surface glycoprotein, mediates
cell–cell and cell–matrix interactions
— Nervous system
— Various epithelia
— Hematopoietic system: NK cells
(80–90%), NKT cells
Strong expression in 78% of
MM patients
[113]
Kappa light chain Immunoglobulin light chain —Mature B cells Surface expression in 35% of
MM patients
[152]
Lewis Y antigen Cell surface antigen present on glycoconjugates,
involved in cellular motility and adhesion
— Epithelial cells (lung, breast,
prostate, stomach, pancreas, uterus and ovary)
— Peripheral blood granulocytes
Expression in 52% of MM patients [116]
BCMA TNFR-family protein, pro-survival upon
binding to its ligands BAFF and APRIL
—Mature B cells
— Plasma cells (selectively
induced during differentiation)
— Nearly absent on naive and memory B cells
Expression by all myeloma
cells and by myeloma cell
lines (4/5)
[115]
CD44v6 Transmembrane glycoprotein, CD44 isoform,
hyaluronate-binding adhesion molecule.
— Squamous epithelia (skin, cervix,
oral mucosa, esophagus)
—Myoepithelia (breast, prostate)
— Type II pneumocytes
Expression in 43% to 87% of
symptomatic MM patients
[117]
CS1 Cell surface glycoprotein, involved in
cell–cell and cell–matrix interactions
— Plasma cells
— NK cells and subsets of T cells
— Activated monocytes and DCs
Expression (RNA/protein) in
(all/majority) of MM patients
[107,111]
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production. The anti-MM function of CS1-CAR NK cells was evaluated
in vitro and in vivo in an IM9-Luc-xenografted NSG mouse model
[107]. CS1-CAR NK cells had an increased cytolytic activity against
CS1-positive myeloma cell lines compared to unmodiﬁed NK cells. Fol-
lowing adoptive transfer of CS1-CAR NK cells, the total tumor load
was signiﬁcantly decreased in IM9-Luc tumor-bearing mice and their
survival was signiﬁcantly prolonged compared to mice that received
mock-transduced control NK cells [107]. Similar results were obtained
with CAR NK cells directed against CD138 in a MM xenograft NOD-
SCID model. Interestingly, high-dose irradiation did not attenuate the
cytotoxicity of these cells but instead intensiﬁed the anti-tumor re-
sponse [110].
Using the CS1-CAR construct, Chu et al. also generated CS1 CAR T
cells and obtained similar results as with the NK cells. CS1-CAR T cells
showed enhanced in vitro cytotoxicity against CS1-expressingmyeloma
cells, and adoptive transfer into a NSG xenograft mousemodel efﬁcient-
ly suppressed the growth of humanMM.1S and IM9 myeloma cells and
signiﬁcantly prolonged survival [111].Multiple additional antigenshave
been used as targets for the generation of CAR T cells. Anti-CD38 CAR T
cells showed a highly cytotoxic, dose-dependent effect on CD38+
RPMI8226 MM cells and primary MM cells while no cytotoxicity was
observed on CD38− MM cell lines [112]. CD56 is strongly expressed
on malignant plasma cells in 78% of patients with myeloma and repre-
sents another potential immunotherapeutic target. Anti-CD56 CAR T
cells showed antigen-dependent proliferation, cytokine secretion and
cytotoxicity when stimulated with CD56 positive myeloma cells. In
addition, intravenous injection of anti-CD56 CAR T cells in OPM2-
bearing NOD/scid/IL2Rαnull mice resulted in a dose-dependent tumor
eradicationwith persistent anti-CD56 CAR T cells that could be retrieved
from the circulation even 3 months after injection [113].Whether these
mice are less prone to develop tumors when re-challenged with an
OPM2 injection is not clear yet. B-cell maturation antigen (BCMA) is
expressed by MM cell lines and on the surface of primary human MMcells [114]. Anti-BCMA CAR T cells produced large amounts of IFN-γ in
co-cultures with BCMA-expressing MM cell lines and were able to kill
human primary MM cells and MM cell lines that express BCMA (H929
and RPMI-8226). Moreover, anti-BCMA CAR T cells eliminated subcuta-
neous plasmacytomas derived from RPMI-8226 cells in NSG mice,
resulting in the survival of these mice, whereas controls died with pro-
gressive tumors [115]. The Lewis-y (Ley) antigen is a blood group-
related antigen that is expressed in over 70% of epithelial cancers and
in approximately half of primary myeloma samples. Anti-Lewis CAR T
cells secreted IFN-γ in response to RPMI-8226 human myeloma cells
and speciﬁcally lysed Ley-positive myeloma cells. In addition, intra-
venous injections of anti-Lewis CAR T cells in myeloma-bearing NOD/
SCID mice grafted with RPMI-8226 cells resulted in a signiﬁcant
improvement of survival compared with mice treated with non-
transduced T cells [116]. Anti-CD44v6 CAR T cells were generated by
retroviral transduction of T cells with a CAR that consists of the Fab do-
main of the anti-CD44v6 antibody bivatuzumab linked to an intracellu-
lar CD3ζ/CD28 domain [117]. This yielded T cells that displayed the
appropriate in vitro anti-CD44v6 effector functions and that inhibited
MM tumor formation in xenograft models. However, monocytopenia
was observed in mice treated with anti-CD44v6 CAR T cells due to
the expression of this antigen on circulating monocytes. This toxic
side-effect could be avoided by co-transduction of a suicide gene
that ensured a rapid elimination of CD44v6-CAR T cells. Taken to-
gether, these studies suggest that adoptive transfer with CAR NK
and T cells is a promising immunotherapy for MM. Currently, two
clinical trials using CAR T cells to treat MM are ongoing, using CARs
which target the kappa immunoglobulin light chain and CD138
[118].
5. Dendritic cell vaccination
In the past decade, DC vaccination has been explored as a targeted
therapeutic approach for the treatment of cancer and of MM in
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DC vaccination strategy, such as choosing an optimal antigen, mode of
delivery and timing of vaccination, and how to overcome the immune
paresis of myeloma itself [119].
Myeloma vaccination was ﬁrst attempted in the immunocompetent
MOPC315 model [120,121]. These cells express a speciﬁc IgA para-
protein (M315), and prophylactic vaccination with this protein
protected mice against inoculation with MOPC315 cells [122]. Subse-
quently, a speciﬁc Id-peptide of M315 presented in an MHC II context
was discovered (amino acid 91–101 of the γ2 light chain) [123,124],
and a transgenic mouse strain expressing a TCR speciﬁc for this Id-
peptide was generated [125]. Immune rejection in these TCR transgenic
mice is dependent on paraprotein secretion by the injected MOP315
cells. The paraprotein is internalized by DCs through endocytosis
[126], processed and presented in an MHC II context, resulting in the
activation of Id-speciﬁc transgenic CD4 T cells in the draining lymph
nodes. These cells then migrate to the incipient tumor site and secrete
IFN-γ that activates macrophages, resulting in a further inhibition of
tumor growth [127].
Of note, once the tumor burden exceeds a certain threshold in the
MOPC315 model, with M-protein levels exceeding 50 μg/ml, central
and peripheral tolerance is induced [37,128]. The concept of T-cell
exhaustion caused by Id-protein in established disease is further sup-
ported by amurine study inwhich the combination of Id-pulsedDC vac-
cination with syngeneic SCT was evaluated [129]. Brieﬂy, Balb/c mice
were inoculated with HOPC-1F cells and tumor-bearing animals were
immunized with an Id-pulsed DC vaccine that resulted in a prolonged
survival of thesemice compared to controls. However, all animals even-
tually died from their disease. Mice receiving syngeneic transplantation
underwent 7.5 Gy total body irradiation 2 days after HOPC inoculation,
followed by the transfer of G-CSF mobilized syngeneic peripheral blood
progenitor cells. Similar to Id-pulsed DC vaccination as sole therapy,
syngeneic SCT alone did not result in long-term survival. Conversely,
when combining Id-pulsed DC vaccination with syngeneic SCT, long-
term survival was observed in 78% of animals, suggesting that Id-T cell
exhaustion was less prevalent.
As the immunogenicity of Id-vaccines can be poor, homodimeric fu-
sionDNAvaccines, delivered by intramuscular injection,were evaluated
in the MOPC315 model [130]. The fusion proteins, called vaccibodies,
consist in the variable fragment of an Id single chain (the tumor anti-
gen) and a targeting moiety directed towards antigen-presenting cells
(APC), for example the single chain variable fragment of APC-speciﬁc
antibodies (anti-MHC II, anti-CD40) or chemokines (MIP1α, RANTES)
[131–134]. Structural modiﬁcations to vaccibodies, like the generation
of bivalent vaccines and the introduction of xenogeneic sequences, fur-
ther enhanced the effectiveness of the chemokine-Id DNA vaccines
[134]. Using a similar technique, a dickkopf-1 hybrid DNA vaccine was
shown to confer immunity in mice inoculated with MOPC-21 or with
established plasmacytoma [135]. In addition, co-injection of PD-L1-
blocking or CD134-agonist antibodies further enhanced the vaccination
efﬁcacy, underscoring the potential of interfering with checkpoint
mediators. This ﬁnding was corroborated in a separate study exploring
the efﬁcacy of PD-L1 blockade in a whole-cell vaccination model in
5T33 mice [136]. The use of dickkopf-1 as a tumor antigen has clinical
promise because its expression is restricted to myeloma cells, with the
exception of prostate and placental tissues. The importance of antigen
choice and thus optimal vaccine formulation was further demonstrated
in a murine model of J588L plasmacytoma, i.e. a J588 cell line that
has lost the expression of antibody H chain. In this model, Id-keyhole
limpet hemocyanin (KLH)-loaded DC vaccines were inefﬁcient to
prevent tumor development in J588L-inoculated mice, in contrast to
J588 mice. However, direct intra-tumoral injection of naive DCs and
subcutaneous injections of DCs loaded with irradiated tumor cells did
result in a signiﬁcant anti-myeloma effect [137]. These ﬁndings support
the notion that T-cell responses after paraprotein-pulsedDC vaccination
are primarily directed against peptides derived from thecomplementarity determining regions of the H-chain, andmay be futile
in patients with light chain myeloma. Conversely, vaccination with
tumor cell-loaded DC may induce an effective anti-tumor response.
This is further underlined by the ﬁnding that tumor lysate-pulsed DCs
were found to be superior to Id-KLH-pulsed DCs in terms of promoting
anti-tumor immunity [138].
Fusion of myeloma cells to DCs could circumvent the cumbersome
choice of a tumor antigen. Proof of principle of this approach in amurine
myeloma model was delivered by fusing irradiated native J558 and
engineered J558 cells expressing IL-4 with immature and mature Balb/
c bone marrow-derived DCs [139]. Maturation of DCs in vitro was ob-
tained by adding a high dose of GM-CSF and IL-4 to the culturemedium.
After prophylactic vaccination, especially the IL-4-secreting J558/
mature DC fusion vaccine was able to induce protective immunity
against J558 tumor challenge, illustrating the importance of thematura-
tion status of DCs and the therapeutic potential of gene-modiﬁed tumor
fusion vaccines. Similar results were obtainedwith an analogous model
using CD40L-expressing J558 cells [140].
Prophylactic vaccination with both Id-KLH protein and Id-KLH-
pulsed DCs was able to protect mice from developing myeloma in the
5TGM1myeloma model. However, when used as a therapeutic vaccine,
only the Id-KLH-pulsed DC vaccine was able to retard growth and in-
duce tumor regression. In 60% of the DC-vaccinated mice the pre-
existing tumor could be eradicated and these animals were resistant
to subsequent tumor re-challenge. The difference in vaccination efﬁcacy
was most likely due to an increased cellular immune response utilizing
DC vaccination compared to Id-KLH protein since more anti-Id anti-
bodies were observed in the former setting [141].
Several clinical trials investigating DC vaccination in MM patients
are currently ongoing. Results of phase II trials using Id-pulsed DC vac-
cines conﬁrmed the safety of DC vaccination and the induction of a spe-
ciﬁc anti-myeloma immune response in patients [142,143]. However,
clinical efﬁcacy of Id-pulsed DC vaccines could not be demonstrated
yet, despite disease stabilization in a majority of patients [143]. In an-
other phase II clinical trial, minimal residual disease was targeted in
myeloma patients after auto-SCT using DC/tumor fusion vaccines. The
results were encouraging, as DC/tumor fusion vaccination during
the post-transplantation period resulted in an expansion of myeloma-
speciﬁc T cells and a reduction of minimal residual disease [144].
6. Conclusions
Over the last few years, the idea of blocking cancer progression
through immunological means is slowly becoming a reality. Indeed,
harnessing the inherent properties of the immune system to attack tu-
mors will certainly propel immunotherapy to the forefront of cancer
treatment. Unfortunately, durable immunological control of myeloma
is still rare, and current research aims at optimizing immunotherapeutic
approaches and their clinical results.
Murine myeloma models are an important mean to achieve this
goal, but they can present some limitations for pre-clinical studies. In
order to achieve progress in MM immunotherapy, the use of mouse
models that closely recapitulate human disease, both in development
of the disease and in immunological response of the host, may prove
to be essential. Tumor localization within the bone marrow, obtained
after intravenous injection or direct intra-osseous injection, is crucial
for studying the disease in a representative tumor microenvironment.
This bone marrow localization is often indispensable for myeloma-
related symptoms such as bone lesions and cytopenia. Hence, these
models allow the assessment of new therapeutic approaches in a re-
presentative tumor microenvironment at a relevant MM stage. Optimi-
zation of existing murine models is feasible. For example, a cell line
named MOPC315.BM showing bone marrow tropism was recently de-
rived fromMOPC315 cells [145]. Whereas MM has generally a low pro-
gression rate, with a low proliferative index for primary myeloma cells,
most of the murine myeloma models make use of highly proliferative
401M. Binsfeld et al. / Biochimica et Biophysica Acta 1846 (2014) 392–404and blastic cell lines with tumor development that only takes several
weeks. Thus, the MM growth and differentiation characteristics and as-
sociated immunological alterations might have an impact on the re-
sponse to immunotherapy. A comparison of immunological responses
to MM development in different murine myeloma models would be of
great interest in this context. Several ﬁndings also highlight the impor-
tance of timing for efﬁcient immunotherapy. For example, the disap-
pointing results of anti-Id vaccination trials [146,147] might be due to
a deletion of Id-speciﬁc CD4 T cells in most MM patients at the time of
diagnosis. Thus, the optimal time of vaccination would be in a state of
low residual disease burden and after high-dose chemotherapy, a time
point at which a new repertoire of T cells undergoes thymic education
and Treg levels are low [148]. Finally, promising opportunities for test-
ing immunotherapeutic concepts lie in the use of genetic inducible mu-
rine models of MM since these models resemble human disease with a
similar genetic landscape. In addition, they display a more indolent
tumor growth, with tumor development that takes up to 18 months,
that allows for treatment initiation at a stage more resembling to the
clinical situation. Several of such models have been reported, including
transgenic Eμ-c-MAF and Eμ-XBP1s mice that overexpress these
myeloma-associated genes in an Eμ-dependent B-cell speciﬁc manner
[149,150]. In addition, Chesi et al. generated Vk*MYC transgenic mice
in which the activation of MYC is under the control of the Igκ light
chain gene regulatory elements, developing tumors that are highly ho-
mologous to those observed in human MM [151].
Although allo-SCT is efﬁciently used for the treatment of several
other hematological malignancies, its efﬁciency in MM remains un-
satisfactory, possibly due to immunological suppression of the graft by
residual MM cells. Highly suppressive Tregs expand and accumulate in
the bone marrow after allo-SCT [62], and these cells might be able to
convert into myeloma-promoting Th17 cells [25,85]. Murine studies
suggest that combining allo-SCT with Id- or DC vaccination provides a
possible solution to these issues [81,82]. In addition, new immuno-
therapeutic strategies targeting Th17 cells, but also immune suppres-
sive cells like MDSCs and Tregs, would be of great interest.
To conclude, severalmurinemodels ofMMare available and are being
developed that allow the study of anti-myeloma immunotherapy. These
models permit detailed monitoring of the anti-myeloma immune re-
sponse following treatment with novel immunotherapeutic approaches.
Recently, some of these studies gave rise to clinical trials, bringing cellular
immunotherapy of MM from preclinical models to the bedside.Acknowledgements
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